Estradiol effects on the dopamine transporter – protein levels, subcellular location, and function
Tóm tắt
The effects of estrogens on dopamine (DA) transport may have important implications for the increased incidence of neurological disorders in women during life stages when hormonal fluctuations are prevalent, e.g. during menarche, reproductive cycling, pregnancy, and peri-menopause. The activity of the DA transporter (DAT) was measured by the specific uptake of 3H-DA. We found that low concentrations (10-14 to 10-8 M) of 17β-estradiol (E2) inhibit uptake via the DAT in PC12 cells over 30 minutes, with significant inhibition taking place due to E2 exposure during only the last five minutes of the uptake period. Such rapid action suggests a non-genomic, membrane-initiated estrogenic response mechanism. DAT and estrogen receptor-α (ERα) were elevated in cell extracts by a 20 ng/ml 2 day NGFβ treatment, while ERβ was not. DAT, ERα and ERβ were also detectable on the plasma membrane of unpermeabilized cells by immunocytochemical staining and by a fixed cell, quantitative antibody (Ab)-based plate assay. In addition, PC12 cells contained RNA coding for the alternative membrane ER GPR30; therefore, all 3 ER subtypes are candidates for mediating the rapid nongenomic actions of E2. At cell densities above 15,000 cells per well, the E2-induced inhibition of transport was reversed. Uptake activity oscillated with time after a 10 nM E2 treatment; in a slower room temperature assay, inhibition peaked at 9 min, while uptake activity increased at 3 and 20–30 min. Using an Ab recognizing the second extracellular loop of DAT (accessible only on the outside of unpermeabilized cells), our immunoassay measured membrane vs. intracellular/nonvesicular DAT; both were found to decline over a 5–60 min E2 treatment, though immunoblot analyses demonstrated no total cellular loss of protein. Our results suggest that physiological levels of E2 may act to sequester DAT in intracellular compartments where the transporter's second extramembrane loop is inaccessible (inside vesicles) and that rapid estrogenic actions on this differentiated neuronal cell type may be regulated via membrane ERs of several types.
Tài liệu tham khảo
Williams CL: Estrogen effects on cognition across the lifespan. Horm Behav 1998, 34:80–84.
Greenspan FS, Gardner DG: Appendix: Normal Hormone Reference Ranges. In Basic and Clinical Endocrinology. Volume Appendix. 7th edition. Edited by: Greenspan FS and Gardner DG. New York, Lange Medical Books, McGraw Hill; 2004:925–926.
Halbreich U, Kahn LS: Role of estrogen in the aetiology and treatment of mood disorders. CNS Drugs 2001, 15:797–817.
Staley JK, Sanacora G, Tamagnan G, Maciejewski PK, Malison RT, Berman RM, Vythilingam M, Kugaya A, Baldwin RM, Seibyl JP, Charney D, Innis RB: Sex differences in diencephalon serotonin transporter availability in major depression. Biol Psychiatry 2006, 59:40–47.
Walf AA, Frye CA: A review and update of mechanisms of estrogen in the hippocampus and amygdala for anxiety and depression behavior. Neuropsychopharmacology 2006, 31:1097–1111.
Prior JC: Ovarian aging and the perimenopausal transition: the paradox of endogenous ovarian hyperstimulation. Endocrine 2005, 26:297–300.
Steiner M, Dunn E, Born L: Hormones and mood: from menarche to menopause and beyond. J Affect Disord 2003, 74:67–83.
Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A: Efficacy of a New Low-Dose Oral Contraceptive With Drospirenone in Premenstrual Dysphoric Disorder. Obstet Gynecol 2005, 106:492–501.
Almeida OP, Barclay L: Sex hormones and their impact on dementia and depression: a clinical perspective. Expert Opin Pharmacother 2001, 2:527–535.
Stein D, Hanukoglu A, Blank S, Elizur A: Cyclic psychosis associated with the menstrual cycle. Br J Psychiatry 1993, 163:824–828.
Oinonen KA, Mazmanian D: Does body fat protect against negative moods in women? Med Hypotheses 2001, 57:387–388.
Taylor M: Psychological consequences of surgical menopause. J Reprod Med 2001, 46:317–324.
Soares CN, Poitras JR, Prouty J: Effect of reproductive hormones and selective estrogen receptor modulators on mood during menopause. Drugs Aging 2003, 20:85–100.
Rodie J: [Use of estrogens in the treatment of mental disorders]. Actas Esp Psiquiatr 2003, 31:199–204.
Compton J, van AT, Murphy D: Mood, cognition and Alzheimer's disease. Best Pract Res Clin Obstet Gynaecol 2002, 16:357–370.
Dluzen DE, Mickley KR: Gender differences in modulatory effects of tamoxifen upon the nigrostriatal dopaminergic system. Pharmacol Biochem Behav 2005, 80:27–33.
Foltynie T, Lewis SG, Goldberg TE, Blackwell AD, Kolachana BS, Weinberger DR, Robbins TW, Barker RA: The BDNF Val66Met polymorphism has a gender specific influence on planning ability in Parkinson's disease. J Neurol 2005, 252:833–838.
Benedetti MD, Maraganore DM, Bower JH, McDonnell SK, Peterson BJ, Ahlskog JE, Schaid DJ, Rocca WA: Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: an exploratory case-control study. Mov Disord 2001, 16:830–837.
Quinn PO: Treating adolescent girls and women with ADHD: gender-specific issues. J Clin Psychol 2005, 61:579–587.
Kurlan R: The pathogenesis of Tourette's syndrome. A possible role for hormonal and excitatory neurotransmitter influences in brain development. Arch Neurol 1992, 49:874–876.
Luine VN, Jacome LF, MacLusky NJ: Rapid enhancement of visual and place memory by estrogens in rats. Endocr 2003, 144:2836–2844.
Shively CA, Bethea CL: Cognition, mood disorders, and sex hormones. ILAR J 2004, 45:189–199.
Bender CM, Sereika SM, Berga SL, Vogel VG, Brufsky AM, Paraska KK, Ryan CM: Cognitive impairment associated with adjuvant therapy in breast cancer. Psychooncology 2006, 15:422–430.
Joffe H, Hall JE, Gruber S, Sarmiento IA, Cohen LS, Yurgelun-Todd D, Martin KA: Estrogen therapy selectively enhances prefrontal cognitive processes: a randomized, double-blind, placebo-controlled study with functional magnetic resonance imaging in perimenopausal and recently postmenopausal women. Menopause 2006, 13:411–422.
Elman I, Karlsgodt KH, Gastfriend DR: Gender differences in cocaine craving among non-treatment-seeking individuals with cocaine dependence. Am J Drug Alcohol Abuse 2001, 27:193–202.
Jackson LR, Robinson TE, Becker JB: Sex differences and hormonal influences on acquisition of cocaine self-administration in rats. Neuropsychopharmacology 2006, 31:129–138.
Sell SL, Scalzitti JM, Thomas ML, Cunningham KA: Influence of ovarian hormones and estrous cycle on the behavioral response to cocaine in female rats. J Pharmacol Exp Ther 2000, 293:879–886.
Watson CS, Gametchu B: Proteins of multiple classes participate in nongenomic steroid actions. Exp Biol Med 2003, 228:1272–1281.
Watson CS, Norfleet AM, Pappas TC, Gametchu B: Rapid actions of estrogens in GH3/B6 pituitiary tumor cells via a plasma membrane version of estrogen receptor-". Steroids 1999, 64:5–13.
Bannon MJ: The dopamine transporter: role in neurotoxicity and human disease. Toxicol Appl Pharmacol 2005, 204:355–360.
MacLusky NJ, Chalmers-Redman R, Kay G, Ju W, Nethrapalli IS, Tatton WG: Ovarian steroids reduce apoptosis induced by trophic insufficiency in nerve growth factor-differentiated PC12 cells and axotomized rat facial motoneurons. Neuroscience 2003, 118:741–754.
Gelinas S, Bureau G, Valastro B, Massicotte G, Cicchetti F, Chiasson K, Gagne B, Blanchet J, Martinoli MG: Alpha and beta estradiol protect neuronal but not native PC12 cells from paraquat-induced oxidative stress. Neurotox Res 2004, 6:141–148.
Nilsen J, Mor G, Naftolin F: Raloxifene induces neurite outgrowth in estrogen receptor positive PC12 cells. Menopause 1998, 5:211–216.
Pappas TC, Gametchu B, Watson CS: Membrane estrogen receptors identified by multiple antibody labeling and impeded-ligand binding. FASEB J 1995, 9:404–410.
Campbell CH, Watson CS: A comparison of membrane vs. intracellular estrogen receptor-" in GH3/B6 pituitary tumor cells using a quantitative plate immunoassay. Steroids 2001, 66:727–736.
Razandi M, Pedram A, Greene GL, Levin ER: Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: Studies of ER" and ERß expressed in chinese hamster ovary cells. Mol Endocrinol 1999, 13:307–319.
Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER: A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 2005, 307:1625–1630.
Filardo EJ, Quinn JA, Frackelton AR, Bland KI: Estrogen action via the G protein-coupled receptor, GPR30: Stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol Endocrinol 2002, 16:70–84.
Thomas P, Pang Y, Filardo EJ, Dong J: Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocr 2005, 146:624–632.
Sohrabji F, Greene LA, Miranda RC, Toran-Allerand CD: Reciprocal regulation of estrogen and NGF receptors by their ligands in PC12 cells. J Neurobiol 1994, 25:974–988.
Bulayeva NN, Gametchu B, Watson CS: Quantitative measurement of estrogen-induced ERK 1 and 2 activation via multiple membrane-initiated signaling pathways. Steroids 2004, 69:181–192.
Ciliax BJ, Heilman C, Demchyshyn LL, Pristupa ZB, Ince E, Hersch SM, Niznik HB, Levey AI: The dopamine transporter: immunochemical characterization and localization in brain. J Neurosci 1995, 15:1714–1723.
Lee E, Mun GH, Oh CS, Chung YH, Cha CL, Lee YS, Shin DH: A subcellular distribution of estrogen receptor-alpha is changed during artificially induced senescence of PC12 pheochromocytoma cells. Neurosci Lett 2004, 372:80–84.
Pappas TC, Gametchu B, Yannariello-Brown J, Collins TJ, Watson CS: Membrane estrogen receptors in GH3/B6 cells are associated with rapid estrogen-induced release of prolactin. Endocrine 1994, 2:813–822.
Norfleet AM, Thomas ML, Gametchu B, Watson CS: Estrogen receptor-a detected on the plasma membrane of aldehyde-fixed GH3/B6/F10 rat pituitary cells by enzyme-linked immunocytochemistry. Endocr 1999, 140:3805–3814.
Campbell CH, Bulayeva N, Brown DB, Gametchu B, Watson CS: Regulation of the membrane estrogen receptor-a: role of cell density, serum, cell passage number, and estradiol. FASEB J 2002, 16:1917–1927.
Zivadinovic D, Watson CS: Membrane estrogen receptor-alpha levels predict estrogen-induced ERK1/2 activation in MCF-7 cells. Breast Cancer Res 2005, 7:R130-R144.
Koldzic-Zivanovic N, Seitz PK, Watson CS, Cunningham KA, Thomas ML: Intracellular signaling involved in estrogen regulation of serotonin reuptake. Mol Cell Endocrinol 2004, 226:33–42.
Bulayeva NN, Wozniak A, Lash LL, Watson CS: Mechanisms of membrane estrogen receptor-{alpha}-mediated rapid stimulation of Ca2+ levels and prolactin release in a pituitary cell line. Am J Physiol Endocrinol Metab 2005, 288:E388-E397.
Holton KL, Loder MK, Melikian HE: Nonclassical, distinct endocytic signals dictate constitutive and PKC-regulated neurotransmitter transporter internalization. Nat Neurosci 2005, 8:881–888.
Grigoriadis S, Kennedy SH: Role of estrogen in the treatment of depression. Am J Ther 2002, 9:503–509.
Bloch M, Schmidt PJ, Danaceau M, Murphy J, Nieman L, Rubinow DR: Effects of gonadal steroids in women with a history of postpartum depression. Am J Psychiatry 2000, 157:924–930.
Osterlund MK, Overstreet DH, Hurd YL: The flinders sensitive line rats, a genetic model of depression, show abnormal serotonin receptor mRNA expression in the brain that is reversed by 17beta-estradiol. Brain Res Mol Brain Res 1999, 74:158–166.
Morrison MF, Kallan MJ, Ten HT, Katz I, Tweedy K, Battistini M: Lack of efficacy of estradiol for depression in postmenopausal women: a randomized, controlled trial. Biol Psychiatry 2004, 55:406–412.
Miller KJ: The other side of estrogen replacement therapy: outcome study results of mood improvement in estrogen users and nonusers. Curr Psychiatry Rep 2003, 5:439–444.
Klaiber EL, Broverman DM, Vogel W, Kobayashi Y: Estrogen therapy for severe persistent depressions in women. Arch Gen Psychiatry 1979, 36:550–554.
Lipsett MB: Estrogen use and cancer risk. J Am Med Assoc 1977, 237:1112–1115.
Gorski J, Wendell D, Gregg D, Chun TY: Estrogens and the genetic control of tumor growth. [Review] [23 refs]. Progress in Clinical & Biological Research 1997, 396:233–243.
File SE, Heard JE, Rymer J: Trough oestradiol levels associated with cognitive impairment in post-menopausal women after 10 years of oestradiol implants. Psychopharmacology (Berl) 2002, 161:107–112.
Maki PM: A systematic review of clinical trials of hormone therapy on cognitive function: effects of age at initiation and progestin use. Ann N Y Acad Sci 2005, 1052:182–197.
Simpkins JW, Green PS, Gridley KE, Singh M, de Fiebre NC, Rajakumar G: Role of estrogen replacement therapy in memory enhancement and the prevention of neuronal loss associated with Alzheimer's disease. Am J Med 1997, 103:19S-25S.
Haynes LE, Lendon CL, Barber DJ, Mitchell IJ: 17 Beta-oestradiol attenuates dexamethasone-induced lethal and sublethal neuronal damage in the striatum and hippocampus. Neuroscience 2003, 120:799–806.
vom Saal FS, Hughes C: An extensive new literature concenring low-dose effects of bisphenol A shows the need for a new risk assessment. Environ Health Perspect 2005, 113:926–933.
Blakely RD, Bauman AL: Biogenic amine transporters: regulation in flux. Curr Opin Neurobiol 2000, 10:328–336.
Buckley KM, Melikian HE, Provoda CJ, Waring MT: Regulation of neuronal function by protein trafficking: a role for the endosomal pathway. J Physiol 2000, 525 Pt 1:11–19.
Loder MK, Melikian HE: The dopamine transporter constitutively internalizes and recycles in a protein kinase C-regulated manner in stably transfected PC12 cell lines. J Biol Chem 2003, 278:22168–22174.
Melikian HE: Neurotransmitter transporter trafficking: endocytosis, recycling, and regulation. Pharmacol Ther 2004, 104:17–27.
Gulley JM, Doolen S, Zahniser NR: Brief, repeated exposure to substrates down-regulates dopamine transporter function in Xenopus oocytes in vitro and rat dorsal striatum in vivo. J Neurochem 2002, 83:400–411.
Watson CS: Signaling themes shared between peptide and steroid hormones at the plasma membrane. Sci STKE 1999, 1999:E1.
Torres GE, Gainetdinov RR, Caron MG: Plasma membrane monoamine transporters: structure, regulation and function. Nat Rev Neurosci 2003, 4:13–25.
Zivadinovic D, Gametchu B, Watson CS: Membrane estrogen receptor-alpha levels in MCF-7 breast cancer cells predict cAMP and proliferation responses. Breast Cancer Res 2005, 7:R101-R112.
Gametchu B, Watson CS, Wu S: Use of receptor antibodies to demonstrate membrane glucocorticoid receptor in cells from human leukemic patients. FASEB J 1993, 7:1283–1293.
Gametchu B, Watson CS: Correlation of membrane glucocorticoid receptor levels with glucocorticoid-induced apoptotic competence using mutant leukemic and lymphoma cells lines. Journal of Cellular Biochemistry 2002, 87:133–146.
Marquez DC, Pietras RJ: Membrane-associated binding sites for estrogen contribute to growth regulation of human breast cancer cells. Oncogene 2001, 20:5420–5430.
Song RX, Barnes CJ, Zhang Z, Bao Y, Kumar R, Santen RJ: The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane. Proc Natl Acad Sci U S A 2004, 101:2076–2081.
Funakoshi T, Yanai A, Shinoda K, Kawano MM, Mizukami Y: G protein-coupled receptor 30 is an estrogen receptor in the plasma membrane. Biochem Biophys Res Commun 2006, 346:904–910.
Melikian HE, Buckley KM: Membrane trafficking regulates the activity of the human dopamine transporter. J Neurosci 1999, 19:7699–7710.
Mizuta I, Ohta M, Ohta K, Nishimura M, Mizuta E, Hayashi K, Kuno S: Selegiline and desmethylselegiline stimulate NGF, BDNF, and GDNF synthesis in cultured mouse astrocytes. Biochem Biophys Res Commun 2000, 279:751–755.